DOI:
10.1055/s-00000020
Geburtshilfe und Frauenheilkunde
LinksClose Window
References
Nitz U, Gluz O, Kreipe HH. et al.
The run-in phase of the prospective WSG-ADAPT HR+/HER2-trial demonstrates the feasibility of a study design combining static and dynamic biomarker assessments for individualized therapy in early breast cancer.
Ther Adv Med Oncol 2020;
12
DOI: 10.1177/1758835920973130.
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.